Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 8, November, p. 1231–1236

doi: 10.17219/acem/68627

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Serum osteopontin and vitronectin levels in systemic sclerosis

Baris Gundogdu1,A,D,F, Servet Yolbas1,B, Musa Yilmaz2,C, Suleyman Aydin2,C, Sulayman Serdar Koca1,A,D,E,F

1 Department of Rheumatology, Faculty of Medicine, Firat University, Elazığ, Turkey

2 Department of Biochemistry, Faculty of Medicine, Firat University, Elazığ, Turkey


Background. Osteopontin a matricellular protein has pro-fibrotic effects and binds integrin such as αvβ1 and αvβ3. Vitronectin is one of the integrin αvβ3 ligands and is a multifunctional glycoprotein.
Objectives. The aim of the present study was to evaluate serum osteopontin and vitronectin levels in a cohort of patients with systemic sclerosis (SSc).
Material and Methods. Eighty-six patients with SSc, 46 patients with systemic lupus erythematosus (SLE), and 38 healthy controls (HC) were enrolled in the study. Serum osteopontin, vitronectin, IL-6, and TGF-β levels were analyzed.
Results. Serum osteopontin levels were higher in the SSc and SLE groups compared to the HC group (p < 0.01 and p < 0.001, respectively). However, it was not correlated with disease activity and severity scores in the SSc group. On the other hand, serum vitronectin levels were lower in the SSc group than in the SLE and HC groups (p < 0.001 for both).
Conclusion. These results may suggest that osteopontin levels may be increased due to the inflammatory process and osteopontin has not a specific role on fibrosis in SSc. On the other hand, serum vitronectin levels decrease in SSc in contrast to SLE. It may be concluded that the one cause of decreased serum vitronectin levels in SSc may be its accumulation in fibrotic area.

Key words

systemic sclerosis, osteopontin, vitronectin

References (39)

  1. Varga J, Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557–567.
  2. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: Fibrotic diseases: Cellular and molecular mechanisms and novel therapies. Ann Intern Med. 2010;152:159–166.
  3. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol. 2006;2:134–144.
  4. Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: The role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther. 2007;9(Suppl 2).
  5. Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: Possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol. 2004;16:733–738.
  6. Wang KX, Denhardt DT. Osteopontin: Role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19:333–345.
  7. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011;5:111–122.
  8. Rittling SR. Osteopontin in macrophage function. Exp Rev Mol Med. 2011;13:e15.
  9. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science. 2000;287:860–864.
  10. Zheng W, Li R, Pan H, et al. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum. 2009;60:1957–1965.
  11. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ Res. 2008;102:319–327.
  12. Gardner H, Shearstone JR, Bandaru R, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum. 2006;54:1961–1973.
  13. Barizzone N, Marchini M, Cappiello F, et al. Association of osteopontin regulatory polymorphisms with systemic sclerosis. Hum Immunol. 2011;72:930–934.
  14. Lorenzen JM, Krämer R, Meier M, et al. Osteopontin in the development of systemic sclerosis-relation to disease activity and organ manifestation. Rheumatology (Oxford). 2010;49:1989–1991.
  15. Wu M, Schneider DJ, Mayes MD, et al. Osteopontin in systemic sclerosis and its role in dermal fibrosis. J Invest Dermatol. 2012;132: 1605–1614.
  16. Horton MA. The alpha v beta 3 integrin “vitronectin receptor”. Int J Biochem Cell Biol. 1997;29:721–725.
  17. Chen W, Rock JB, Yearsley MM, Ferrell LD, Frankel WL. Different collagen types show distinct rates of increase from early to late stages of hepatitis C-related liver firbosis. Hum Pathol. 2014;45:160–165.
  18. Carpagnano GE, Kharitonov SA, Wells AU, Pantelidis P, Du Bois RM, Barnes PJ. Increased vitronectin and endotelin-1 in the breath condensate of patients with fibrosing lung disease. Respiration. 2003;70:154–160.
  19. López-Guisa JM, Rassa AC, Cai X, Collins SJ, Eddy AA. Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease. Am J Physiol Renal Physiol. 2011;300:1244–1254.
  20. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–590.
  21. van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis. 2013;72:1747–1755.
  22. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–2686.
  23. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–1285.
  24. Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol. 1999;26:2159–2167.
  25. Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592–598.
  26. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The Health Assesment Questionnaire, disability and pain scales. J Rheumatol. 1982;9:789–793.
  27. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin – A molecule for all seasons. QJM. 2002;95:3–13.
  28. Rullo OJ, Woo JM, Parsa MF, et al. Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus. Arthritis Res Ther. 2013;15(1):R18.
  29. Ji HI, Lee SH, Song R, et al. Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis. Clin Rheumatol. 2014;33(3):397–402.
  30. Erturkler E, Cicek D, Kaman D, Ozdogan S, Bakar Dertlioglu S. Plasma osteopontin levels in patients with Behcet’s disease and psoriasis. Eur J Dermatol. 2011;21:203–208.
  31. Schvartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol. 1999;31:539–544.
  32. Hayman EG, Pierschbacher MD, Ohgren Y, Ruoslahti E. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci USA. 1983;80:4003–4007.
  33. Mayasundari A, Whittemore NA, Serpersu EH, Peterson CB. The solution structure of the N-terminal domain of human vitronectin: Proximal sites that regulate fibrinolysis and cell migration. J Biol Chem. 2004;279:29359–29366.
  34. Preissner KT. The role of vitronectin as multifunctional regulator in the hemostatic and immune systems. Blut. 1989;59:419–431.
  35. Koca SS, Kara M, Ozgen M, et al. The rs3768777-G allele of ITGAV gene is associated with rheumatoid arthritis. Rheumatol Int. 2014;34:693–698.
  36. Manetti M, Rosa I, Milia AF, et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: A new model of experimental scleroderma? Ann Rheum Dis. 2014;73:1700–1709.
  37. Jang YC, Tsou R, Gibran NS, Isik FF. Vitronectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice. Surgery. 2000;127:696–704.
  38. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am J Pathol. 2004;164:1275–1292.
  39. Asano Y, Ihn H, Jinnin M, Mimura Y, Tamaki K. Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-β signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol. 2006;126:1761–1769.